Presented by The Conference Forum in collaboration with the Society for Immunotherapy of Cancer.
With promising cancer immunotherapies in the clinic and an encouraging pipeline of new targets being developed, additional discoveries are now under way to determine the most effective immuno-oncology combinations for individual patients and for specific tumor types. Increased emphasis on prioritizing combinations will be crucial for decision-making. As a result, novel therapies and innovative trial designs are creating increased momentum for investment/business development opportunities. IO Combinations 360° will provide up-to-date progress on combination developments in terms of business aspects, clinical advancements and scientific data to prioritize cancer treatments for individual patients and tumor types.
IO Combinations 360° is a comprehensive program providing exposure to the entire spectrum of R&D, addressing key aspects across all facets of combination immunotherapies including: discovery/preclinical science, bispecifics, translational science, biomarkers, next generation cell therapy, clinical developments, operationalizing combinations, business aspects, and emerging technologies and trends in the field.
SITC Member Leaders:
Dan Chen, MD, PhD - IGM Biosciences
Omid Hamid, MD - The Angeles Clinic
James L. Gulley, MD, PhD - NIH
Use the code SITC20 for a 20% discount.
For more information please visit: www.io360summit.com